CRISPR/Cas9 gene knockout technology was utilized to target the CCAT2 gene in CRC cells HCT116 and HT29, with one upstream and one downstream target being designed (gRNA‐A1: TTACGGTTCATCACCAATAGTGG, gRNA‐A2: CACCAATAGTGGCAGAGGATGGG). This evidence concerns the gene CCAT2 and colorectal carcinoma.